Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: A pilot study

Wei Chen, Michal L. Melamed, Thomas H. Hostetter, Carolyn Ann Bauer, Amanda C. Raff, Anthony L. Almudevar, Amy Lalonde, Susan Messing, Matthew K. Abramowitz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD. Methods: This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15-45 mL/min/1.73 m2 and serum bicarbonate between 20-24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate. Results: After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7-267.43) to 191.4 RU/mL (IQR 132.6-316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D. Conclusions: FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors. Trial registration: The study was registered at ClinicalTrials.gov (NCT00888290) on April 23, 2009.

Original languageEnglish (US)
Article number114
JournalBMC Nephrology
Volume17
Issue number1
DOIs
StatePublished - Aug 5 2016

Fingerprint

Sodium Bicarbonate
Chronic Renal Insufficiency
Bicarbonates
Acidosis
Placebos
Single-Blind Method
fibroblast growth factor 23
Glomerular Filtration Rate
Vitamin D
Bone and Bones
Therapeutics
Serum

Keywords

  • Alkali therapy
  • Fibroblast growth factor-23
  • Metabolic acidosis
  • Mineral metabolism
  • Sodium bicarbonate
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology

Cite this

Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease : A pilot study. / Chen, Wei; Melamed, Michal L.; Hostetter, Thomas H.; Bauer, Carolyn Ann; Raff, Amanda C.; Almudevar, Anthony L.; Lalonde, Amy; Messing, Susan; Abramowitz, Matthew K.

In: BMC Nephrology, Vol. 17, No. 1, 114, 05.08.2016.

Research output: Contribution to journalArticle

@article{62c3b1b281e34917801c7a6d8d9ff773,
title = "Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: A pilot study",
abstract = "Background: The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD. Methods: This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15-45 mL/min/1.73 m2 and serum bicarbonate between 20-24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate. Results: After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7-267.43) to 191.4 RU/mL (IQR 132.6-316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D. Conclusions: FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors. Trial registration: The study was registered at ClinicalTrials.gov (NCT00888290) on April 23, 2009.",
keywords = "Alkali therapy, Fibroblast growth factor-23, Metabolic acidosis, Mineral metabolism, Sodium bicarbonate, Vitamin D",
author = "Wei Chen and Melamed, {Michal L.} and Hostetter, {Thomas H.} and Bauer, {Carolyn Ann} and Raff, {Amanda C.} and Almudevar, {Anthony L.} and Amy Lalonde and Susan Messing and Abramowitz, {Matthew K.}",
year = "2016",
month = "8",
day = "5",
doi = "10.1186/s12882-016-0331-6",
language = "English (US)",
volume = "17",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease

T2 - A pilot study

AU - Chen, Wei

AU - Melamed, Michal L.

AU - Hostetter, Thomas H.

AU - Bauer, Carolyn Ann

AU - Raff, Amanda C.

AU - Almudevar, Anthony L.

AU - Lalonde, Amy

AU - Messing, Susan

AU - Abramowitz, Matthew K.

PY - 2016/8/5

Y1 - 2016/8/5

N2 - Background: The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD. Methods: This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15-45 mL/min/1.73 m2 and serum bicarbonate between 20-24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate. Results: After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7-267.43) to 191.4 RU/mL (IQR 132.6-316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D. Conclusions: FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors. Trial registration: The study was registered at ClinicalTrials.gov (NCT00888290) on April 23, 2009.

AB - Background: The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD. Methods: This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15-45 mL/min/1.73 m2 and serum bicarbonate between 20-24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate. Results: After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7-267.43) to 191.4 RU/mL (IQR 132.6-316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D. Conclusions: FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors. Trial registration: The study was registered at ClinicalTrials.gov (NCT00888290) on April 23, 2009.

KW - Alkali therapy

KW - Fibroblast growth factor-23

KW - Metabolic acidosis

KW - Mineral metabolism

KW - Sodium bicarbonate

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84982814946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982814946&partnerID=8YFLogxK

U2 - 10.1186/s12882-016-0331-6

DO - 10.1186/s12882-016-0331-6

M3 - Article

C2 - 27495287

AN - SCOPUS:84982814946

VL - 17

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 114

ER -